Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Transparency Initiative: Disclosure Rules Could Expand, Then Be Harmonized

Executive Summary

Following the release of FDA's Transparency Task Force report, the agency may want to add an agenda item to its harmonization discussions with EMA

Related Content

FDA Pushes Back Against “Living” Benefit-Risk Assessment Management Plan
BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA
Disclosing Drug Development Failures Would Aid Regulatory Science, FDA’s Hamburg Says
FDA’s Congressional Relations, Internal Structure May Change With Sharfstein’s Departure
From Beginning To End, FDA Transparency Weighed On Sharfstein’s Mind
Behind Closed Doors: FDA Drug Safety Board Will Keep Its Decisions Private
Can FDA Do The "Right Thing" On Transparency? Ask A Lawyer
Avandia Aftershocks: Will FDA Drug Safety Review Structures Crumble?
FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates
EU Regulator Wants Closer Ties With Health Technology Assessors





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts